Cannabinoid Transdermal Therapy

About A-Synaptic Pharma

A-Synaptic Pharma is an early-stage biotech focused on revolutionizing cannabinoid therapeutics through its advanced transdermal 'liquid needle' delivery platform, GT4. The company's technology aims to overcome the challenges of delivering lipophilic cannabinoid molecules through the skin, offering precise dosing, rapid absorption, and avoidance of first-pass liver metabolism. Its lead development program targets pediatric epileptic seizures, and it has completed a human bioavailability study in Canada, positioning it to pursue clinical development in the United States.

Therapeutic Areas